I'm no guru. I'm a science guy. I've had my share of losses... Especially ZLCS!! That being said, I would choose ISR over ONCS. I am not invested in either now... Most of all my biotech money is in IDRA. Even if 8400 fails, we will get rich on GSO. I'm patient!
ISR is better than ONCS-- it has an approved product and is a buyout candidate. It has NO downside from its current price. ONCS can go to zero if it fails. Also consider APRI.. Won't go any lower
You gotta look at market cap, and not dwell on stock price. Adxs tripled from $2.50 to $7.50-- it didn't fit your "under $1" criterion, but it had a small number of shares and low market cap.
LOL. You're working hard today already!
Not much time left for you.
Golden Cross on friday, next week we fly...
well, I think that ONCS has over 200 Mil outstanding shares, which will limit its upside. Can't compare that at all to IDRA when it was less than $1 per share.
I'd go for ISR
Each 8400 dosage escalation cohort group is critical to study for side effects. Blocking TLR's 7-9, while treating autoimmune disease and cancer, suppresses the immune system against bacterial and fungal infections. Finding the perfect dosage is critical. These early 8400 trials have to be done meticulously. They know what they have. This is big.
World's #1 profitable drug: Humira $12 Bil sales
#2 is Enbrel $8.5 Bil sales...
If/when 8400 is approved for Dermatomyositis it will compete directly and may in fact treat all the same diseases as Humira with less side effects. Yes, it could be the #1 drug in the world some day. And 9200 May be even better. Another shot on goal.
And when does GSO start?
Yep. It's getting riskier to hold short. Like I've said, we're going to get a pre-market announcement and a big gap up open some time in January, imo. The days of going up or down nickels or dimes will be over.
Agree..$3.84, or $3.50 or $3.94, whatever... it's all good...
Witihin a few weeks, we'll get an AM announcement and open gap up at least of couple of dollars anyway...
Thanks you too. Wonder when the shorts will throw in the towel. This stock has buyout written all over it
With recent buyouts and some crazy biotech valuations (like JUNO after ipo), I'm more convinced than ever that we are still way undervalued, and that the whole sector will have a great 2015..